Peptides / Gut and digestion
Synthetic analog
PN-943
PN-943 is an experimental oral peptide that blocks alpha4beta7 integrin in the gut, studied up to phase 2 for ulcerative colitis and not approved. A study in healthy volunteers tested mostly how the body handles it. PepBank shows 13 results on PN-943 from 1 study in people. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.
Also known as PN 10943A, PN-10943, PN-10943-A, PTG-943
Evidence level: Some studies in people13 of 13 results come from studies in people.
Results in people
13
100% of 13 results
Results in animals
0
0% of 13 results
Results in lab cells
0
0% of 13 results
From computer models
0
0% of 13 results
Overview
PN-943 at a glance
| What it is | Synthetic analog |
|---|---|
| Approval | Regulatory status not recorded |
| In sport | Status unknown |
| Studies | 1 study with results. It gave PN-943, with 13 results. 13 in people |
| Best study in people | Non-randomized trial (2021) |
| Clinical trials | 1 registered: 0 active or planned, 0 with posted results |
The science
What is PN-943?
An oral, gut-restricted integrin antagonist studied for ulcerative colitis.
13
Study results in PepBank
The history of PN-943
- 2020August
A registered trial of PN-943 started (NCT04504383).
- 2021
The oldest paper on PN-943 in PepBank is from 2021.
PN-943 structure and chemistry
The key facts about the molecule. Long codes are in the closed section below.
Structure
PN-943 is a synthetic analog, with a ring, no changed amino acids.
Targets
ITGA4 (gene ITGA4): antagonistEvidence: Primary pharmacology paper and reviewed human UniProt entryITGB7 (gene ITGB7): antagonistEvidence: Primary pharmacology paper and reviewed human UniProt entry
Development
Protagonist Therapeutics. Highest phase: phase 2.
The evidence
What PN-943 studies show
Results grouped by what the studies measured. Each card shows where its results come from.
Some studies in people13 of 13 results come from studies in people.
All 1 study in people
Key PN-943 studies
Studies in people come first, then studies in animals and in the lab.
- PeopleSingle- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers13 resultsModi et al. 2021 · Clinical pharmacology in drug development · cited by 14
PN-943 clinical trials
ClinicalTrials.gov lists 1 trial of PN-943. 0 are active or planned, and 0 have posted results. PepBank does not show trial results.
Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
Phase 2completed169 people
Status and safety
Is PN-943 approved?
FDA
United States
Status unknownStatus unknown.
EMA
European Union
Status unknownStatus unknown.
WADA
Sport
Not recordedStatus unknown.
Regulatory status not recorded. Status unknown.
Laws and labels change, so check the regulator for the current status.
PN-943 side effects and safety
PepBank has 1 safety result from studies of PN-943. 1 of them come from studies in people.
Safety results from studies (1)
- In healthy volunteers, nobody stopped PN‑943 because of treatment-emergent side effects. (Clinical pharmacology in drug development, 2021)
Questions and more
Ask a question about PN-943
The answer links to every study it uses.
Sources
- Database: PepBank data for PN-943 (data version 308560)
- Regulator: FDA status record
- Regulator: EMA status record
- Regulator: WADA status record
- Trial registry: ClinicalTrials.gov
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Ask your AI about PN-943
Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).